CD34 and Schnyder corneal dystrophy: To further the discovery of small molecule therapeutics to treat SCD, we developed an integrative workflow comprised of three components: 1) engineering of a robust human erythroid HbF reporter cell line; 2) high-throughput HbF phenotypic screening of dense small molecule libraries; and 3) orthogonal validation of lead HbF therapeutics in a preclinical primary human CD34+ HSC assay.